Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX29 Vimseltinib
D13166 Vimseltinib dihydrate <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, CSF1R
Vimseltinib
D13166 Vimseltinib dihydrate
Target-based classification of drugs [BR:br08310]
Signaling molecules and receptors
Cytokine receptors
CSF and other factor receptors
CSF1R (FMS, CD115)
D13166 Vimseltinib dihydrate <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D13166
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D13166
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D13166